ETHIQA XR (BUPRENORPHINE EXTENDED-RELEASE INJECTABLE SUSPENSION) 1.3 MG/ML
Live / Registered — Registered (as of 22 Sept 2020)
What this means for you
Registered since 22 Sept 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87703113
- Registration number
- 6158527
- Mark type
- Design + words
- Filed
- 30 Nov 2017
- Published for opposition
- 18 Sept 2018
- Registered
- 22 Sept 2020
- Attorney of record
- Frederic M. Wilf
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, buprenorphine extended release injectable suspension to provide analgesia for laboratory animals
Owner
- FIDELIS ANIMAL HEALTH, INC., NORTH BRUNSWICK, NJ, US
- FIDELIS PHARMACEUTICALS, INC., NORTH BRUNSWICK, NJ, US
- FIDELIS PHARMACEUTICALS LLC, North Brunswick, NJ, US
- FIDELIS PHARMACEUTICALS LLC, North Brunswick, NJ, US
- FIDELIS PHARMACEUTICALS LLC, New Rochelle, NY, US
Prosecution history
- 22 Sept 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 22 Jun 2022 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 19 May 2022 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 22 Sept 2020 — REGISTERED-PRINCIPAL REGISTER
- 21 Aug 2020 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 20 Aug 2020 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 19 Aug 2020 — STATEMENT OF USE PROCESSING COMPLETE
- 17 Aug 2020 — TEAS STATEMENT OF USE RECEIVED
- 07 Jul 2020 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 07 Jul 2020 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 07 Jul 2020 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 04 Apr 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Apr 2020 — SOU EXTENSION 3 GRANTED
- 02 Apr 2020 — SOU EXTENSION 3 FILED
- 02 Apr 2020 — SOU TEAS EXTENSION RECEIVED